Ling Liu

About Ling Liu

Dr. Ling Liu is the Chief Scientific Officer of the Biotherapeutic Discovery Research in Eli Lilly and Company. She received her BS degree in College of Life Science at Sichuan University in and her MSc. Degree in Genetic Institute, Chinese Academy of Science. She received her Ph.D. on Molecular Biology from Western University in Canada. She joined Eli Lilly Biotherapeutic Discovery Research in 1997 after conducting a postdoctoral research at the British Columbia Cancer Research Center in Vancouver. She is passionate to discover and develop novel game change medicines to help patients around the world. Over the years, she has contributed to many experimental biotherapeutics from Concept to Candidate Selection and clinical development for treatment of autoimmune diseases, cancer, diabetes, neuron degeneration and pain. She is the scientific team leader and a co-inventor for Ixekizumab (Taltz) and many other experimental biotherapeutics. Her research contributed to over 25 drug candidates entered clinic including COVID-19 antibodies. She contributed to key biotherapeutic platforms and modalities including bispecific Antibody, protein / petite drugs, antibody drug conjugation and antibody siRNA conjugation for selective delivery to specific cells and tissues. She has collaborated scientists broadly inside and outside of the company. She has served in the Biologic Strategy Committee, Biotherapeutic Leadership Team, Immunology Discovery Strategy Group, Research Leadership Team overseeing all therapeutic indications. She has sponsored Lilly ADC Platform and Antibody siRNA Conjugation Platform. During 26 years R&D at Lilly, Dr. Ling Liu contributed launched multiple Biotherapeutics and a dozen at different stages of clinic development. She was an advisor for Women CEOs of Start-up Companies through Lilly-Springboard Enterprise collaborations in 2018. Dr. Liu is passionate about mentoring others. She has championed for DEI (diversity, Equity and Inclusion) at working place and community.Specialties: discovery and development of antibody & protein as novel medicines,Growth factor and receptor biology,ImmunoOncology and immunology,Cancer biology,Target identification and validation,Therapeutic antibody,Bispecific antibodies,Antibody drug conjugation,antibody siRNA conjugation,Cell-based assays,Biomarker identification,Biotherapeutic for Oncology, autoimmune diseases, diabetic complications, neuron degeneration and pain,Scientific Team Leader for 20 projects including IL-17 antibody and PD1/CD137 Bispecific antibody

Experience

1. Senior Research Fellow

   Eli Lilly and Company

   Oct 2016 — Present

Education

• Western University

  Ph.D., Molecular Biology - Regulation ubiquitin gene expression in response to heat shock

  1987 — 1992

• Chinese Academy of Sciences, Genetic Institute, Beijing, China

  MS, Thesis Title:Changes in Protein Synthesis during Retinoic Acid Induced-differentiation of Tumor cell

  1983 — 1986

• Sichuan University

  BS, Biology

  1979 — 1983

Skills

• Biomarkers
• In Vivo
• Drug Development
• Cancer
• Biopharmaceuticals
• Biologics
• Life Sciences
• In Vitro
• Lifesciences
• Clinical Development
• Validation
• Oncology
• Biochemistry
• Biotechnology
• Target Identification
• Protein Chemistry
• Biomarker Discovery
• Drug Discovery
• High Throughput Screening
• Diabetes
• Immunology
• Assay Development
• Cell
• Antibodies
• Toxicology
• Ind
• Signal Transduction
• Pharmacology
• Translational Medicine